Article Figures & Data
Figures
- Figure 1.
Biological model of Alzheimer disease.
- Figure 2.
Classification of patients in Alzheimer disease. MCI, mild cognitive impairment.
Tables
- Table 1.
Disease-Modifying Treatments for Alzheimer's Disease in Phase 2 and Phase 3 Clinical Trials
Candidate Clinical Trial Phase Expected Primary Completion Date National Clinical Trial Identifier Anti-Aβ antibodies Gantenerumab Phase 3 May-22 NCT03443973, NCT03444870 BAN2401 Phase 3 Jul-22 NCT03887455 LY3002813 Phase 2 Oct-20 NCT03367403 Anti-tau antibodies ABBV-8E12 Phase 2 Dec-20 NCT02880956 RO7105705 Phase 2 Sep-20 NCT03289143 BACE inhibitors Elenbecestat (E2609) Phase 3 Jun-21 NCT03036280 CNP520 Phase 2/3 Jul-24 NCT03131453 Vaccines CAD106 Phase 2/3 Aug-24 NCT02565511 AADvac1 Phase 2 Jun-19 NCT02579252 Aβ, amyloid-beta; BACE, Beta-secretase.
Clinical trial information was obtained from ClinicalTrials.gov as of June 27, 2019.
Cognitive Domain MMSE (Maximum Score) MoCA (Maximum Score) Orientation: time and place 10 6 Registration 3 — Attention and concentration 5 6 Memory 3 5 Verbal fluency — 1 Language 8 5 Visuospatial abilities 1 5 Abstraction — 2 Total score 30 30 MMSE, Mini-Mental State Exam; MoCA, Montreal Cognitive Assessment.
Test for MCI Due to AD False Positives (in Millions) True Positives (in Millions) Number of Patients Requiring Specialty Referral (in Millions) Proportion of Referred Patients with Confirmed MCI Due to AD MMSE 27.1 5.4 32.6 17% MMSE + plasma Aβ 5.2 5.3 10.4 51% MoCA 21.9 5.6 27.5 20% MoCA + plasma Aβ 4.2 5.4 9.6 56% Aβ, amyloid-beta; AD, Alzheimer disease; MCI, mild cognitive impairment; MMSE, mini-mental state exam; MoCA, Montreal Cognitive Assessment.
Patients with MCI due to AD have both MCI and evidence of Aβ deposition in the brain. We estimated that 10.7 million people in the 55+-year-old population in the United States in 2020 will have MCI. Of these, 6.6 million will also have evidence of Aβ deposition.
